Carbaspirin calcium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Carbaspirin calcium is an NSAID indicated in the treatment of short term pain and fever.

Generic Name
Carbaspirin calcium
DrugBank Accession Number
DB13612
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Weight
Average: 458.436
Monoisotopic: 458.0638211
Chemical Formula
C19H18CaN2O9
Synonyms
  • Carbasalate calcium
  • Carbasalato calcico
  • Carbasalatum calcicum
  • Carbaspirin calcium

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofFever caused by common cold••• •••••••••
Symptomatic treatment ofFever caused by flu like illness••• •••••••••
Symptomatic treatment ofHeadache••• •••••••••
Symptomatic treatment ofPain caused by common cold••• •••••••••
Symptomatic treatment ofPain caused by flu like illness••• •••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCarbaspirin calcium may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Abciximab.
AcarboseCarbaspirin calcium may increase the hypoglycemic activities of Acarbose.
AcebutololCarbaspirin calcium may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Aceclofenac.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Irocophan - TablettenCarbaspirin calcium (250 mg) + Acetaminophen (200 mg) + Caffeine (46 mg)TabletOralDr. A. & L. Schmidgall Gmb H & Co Kg1985-12-02Not applicableAustria flag
Iromin Vitamin C KapselnCarbaspirin calcium (250 mg) + Ascorbic acid (100 mg)CapsuleOralDr. A. & L. Schmidgall Gmb H & Co Kg2009-04-15Not applicableAustria flag

Categories

ATC Codes
N02BA15 — Carbasalate calciumB01AC08 — Carbasalate calcium
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylsalicylic acids
Alternative Parents
Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Ureas / Carboxylic acid salts / Carboxylic acid esters / Organic calcium salts / Carboxylic acids
show 5 more
Substituents
Acylsalicylic acid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carbonic acid derivative / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Carboxylic acid salt
show 13 more
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
N667F17JP1
CAS number
5749-67-7
InChI Key
VYMUGTALCSPLDM-UHFFFAOYSA-L
InChI
InChI=1S/2C9H8O4.CH4N2O.Ca/c2*1-6(10)13-8-5-3-2-4-7(8)9(11)12;2-1(3)4;/h2*2-5H,1H3,(H,11,12);(H4,2,3,4);/q;;;+2/p-2
IUPAC Name
calcium urea bis(2-(acetyloxy)benzoate)
SMILES
[Ca++].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O

References

General References
  1. BASG: Iromin (Carbaspirin Calcium) Oral Tablet [Link]
ChemSpider
20651
ChEMBL
CHEMBL3833325
Wikipedia
Carbasalate_calcium

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCardiovascular Disease (CVD) / Hypertension1
2CompletedTreatmentAtrial Fibrillation / Cerebral Hemorrhage1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder
TabletOral
TabletOral500 mg
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00848 mg/mLALOGPS
logP3.17ALOGPS
logP1.24Chemaxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.41Chemaxon
pKa (Strongest Basic)-7.1Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area66.43 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity55.28 m3·mol-1Chemaxon
Polarizability16.51 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.57314
predicted
DeepCCS 1.0 (2019)
[M+H]+188.93115
predicted
DeepCCS 1.0 (2019)
[M+Na]+195.39137
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:45 / Updated at May 29, 2021 18:11